Skip to main content
Fig. 2 | Journal of Neuroinflammation

Fig. 2

From: Plasma YKL-40 in the spectrum of neurodegenerative dementia

Fig. 2

Influence of genetic and clinical data on plasma YKL-40 concentrations in CJD patients. a YKL-40 in CJD stratified by prion protein gene (PRNP) codon 129 polymorphism (M = methionine, V = valine). Kruskal-Wallis test followed by Dunn’s post hoc test (correction for multiple testing) was applied. b YKL-40 in CJD MM1 and VV2 subtypes. Mann-Whitney U test was used. c YKL.40 concentrations stratified by disease stage at the time of blood collection. Samples were grouped into three categories according to whether they underwent blood uptake in the first (< 0.33), second (0.33–0.66), or third (> 0.66) stage of the disease. Kruskal-Wallis test followed by Dunn’s post hoc test (correction for multiple testing) was applied, *p < 0.05. d Association between YKL-40 concentrations and disease duration (months) in CJD patients. Spearman rank correlation was used

Back to article page